WuXi Biologics Reports Solid 2025 Interim Results

Revenue increased by 16.1% YoY to RMB 9,953.2 million; revenue growth from continuing operations was 20.2% IFRS Gross profit margin expanded by 3.6% YoY to 42.7% EBITDA grew 50.5% YoY and IFRS net profit increased 54.8% YoY Adjusted EBITDA grew 20.6% YoY and adjusted net profit increased...